Shares of Chimerix Inc. (NASDAQ:CMRX) traded up 2.4% on Friday . The company traded as high as $3.91 and last traded at $3.90, with a volume of 254,053 shares changing hands. The stock had previously closed at $3.81.

A number of analysts have recently weighed in on the company. FBR & Co restated a “hold” rating on shares of Chimerix in a research note on Tuesday, May 10th. Zacks Investment Research lowered Chimerix from a “buy” rating to a “hold” rating in a research note on Thursday, May 12th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $16.98.

The firm’s market cap is $184.85 million. The firm’s 50-day moving average is $4.15 and its 200-day moving average is $5.66.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.09. The business had revenue of $1.20 million for the quarter, compared to the consensus estimate of $2.79 million. On average, equities analysts forecast that Chimerix Inc. will post ($2.06) earnings per share for the current fiscal year.

In other Chimerix news, CEO M Michelle Berrey acquired 13,188 shares of the company’s stock in a transaction that occurred on Friday, June 24th. The stock was acquired at an average cost of $3.69 per share, for a total transaction of $48,663.72. Following the transaction, the chief executive officer now directly owns 258,821 shares in the company, valued at $955,049.49. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ernest Mario acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 13th. The shares were acquired at an average price of $4.53 per share, with a total value of $45,300.00. Following the completion of the transaction, the director now owns 331,440 shares in the company, valued at $1,501,423.20. The disclosure for this purchase can be found here.

A number of institutional investors have recently modified their holdings of the company. Jennison Associates LLC boosted its position in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock worth $11,400,000 after buying an additional 515,029 shares during the last quarter. Trexquant Investment LP boosted its position in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 107,484 shares during the last quarter. Finally, Morgan Stanley boosted its position in shares of Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock worth $1,674,000 after buying an additional 92,005 shares during the last quarter.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.